Mogens Vyberg

mogens_vybergNordiQC External Quality Assurance in IHC
A survey of the NordiQC EQA work during 2003-2019 will be given, focusing on the most important results and an analysis of major causes for insufficient immunostaining results, which occur in up to 30% of the submitted cases.
EQA of ‘undifferentiated’ marker analyses
Based on markers included in prof. Bellizzi’s presentation, the NordiQC assessment results comprising tests in the so-called primary panel will be presented and optimal vs. insufficient staining reactions discussed.
EQA of carcinoma marker analyses
Based on markers included in prof. Bellizzi’s presentation, the NordiQC assessment results comprising tests for carcinomas will be presented and optimal vs. insufficient staining reactions discussed.
 
EQA of gastrointestinal and neuroendocrine neoplasia marker analyses
Based on markers included in prof. Bellizzi’s presentations, the NordiQC assessment results comprising tests for GI and NE markers for will be presented and optimal vs. insufficient staining reactions discussed.

Biosketch
Mogens Vyberg was board-certified as specialist in pathology 1984, senior consultant at the Institute of Pathology, Aalborg University Hospital 1988 – 2019, professor of clinical pathology at Aalborg University since 2012 and senior consultant at Hvidovre University Hospital since 2019.
Prof. Vyberg’s main clinical expertise and research fields are gastrointestinal, liver and brain pathology, immunohistochemistry and image analysis. He is author and co-author of about 130  peer reviewed scientific papers and conference abstracts, and several book chapters in these fields. He has been head of the Laboratory for immunohisto-chemistry/R&D at the Institute of Pathology in Aalborg, which carries out quality control and protocol optimization for the world’s leading diagnostics companies.
Prof. Vyberg is co-founder of the international organization Nordic Immunohisto­chemical Quality Control (NordiQC, www.nordiqc.org), which was established in 2003 at the Institute of Pathology, Aalborg University Hospital, and currently serves more about 600 pathology laboratories from more than 50 countries. He was NordiQC scheme director  2003-2019.
Prof. Vyberg has been board member of the International Quality Network Pathology and the International Society for Immunohistochemistry and Molecular Morphology.

Selected references

  1. Røge R, Kristoffersen HL, Bzorek M, Nielsen O, Vyberg M. NordiQC Assessments of Chromogranin A Immunoassays. Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):258-262.

  2. Røge R, Bzorek M, Nielsen O, Vyberg M. NordiQC Assessments of CD117 Immunoassays. Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):87-91. doi: 10.1097/PAI.0000000000000714. PubMed PMID: 30499819

  3. Vyberg M. A Commentary: Quality Assurance in Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2019 Apr 16.

  4. Røge R, Nielsen S, Riber-Hansen R, Vyberg M. Impact of Primary Antibody Clone, Format, and Stainer Platform on Ki67 Proliferation Indices in Breast Carcinomas. Appl Immunohistochem Mol Morphol. 2019 Nov/Dec;27(10):732-739. doi: 10.1097/PAI.0000000000000799. PubMed PMID: 31460869.

  5. Lund H, Nielsen S, Grove A, Vyberg M, Sunde L. p57 in Hydatidiform Moles: Evaluation of Antibodies and Expression in Various Cell Types. Appl Immunohistochem Mol Morphol. 2019 Sep 18. doi: 10.1097/PAI.0000000000000807. [Epub ahead of print] PubMed PMID: 31567274.

  6. Thomsen C, Nielsen S, Nielsen BS, Pedersen SH, Vyberg M. Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene. Appl Immunohistochem Mol Morphol. 2019 Mar 27. doi: 10.1097/PAI.0000000000000760. [Epub ahead of print] PubMed PMID: 30920963.

  7. Cheung CC, Swanson PE, Nielsen S, Vyberg M, Torlakovic EE. Uneven Staining in  Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens. Appl Immunohistochem Mol Morphol. 2018 May/Jun;26(5):299-304.

  8. Røge R, Nielsen O, Bzorek M, Nielsen S, Vyberg M. NordiQC Assessments of PAX8  Immunoassays. Appl Immunohistochem Mol Morphol. 2018 Apr;26(4):221-224.

  9. Vyberg M, Røge R, Bzorek M, Nielsen O. NordiQC Assessments of MSH6 Immunoassays. Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):431-434. doi: 10.1097/PAI.0000000000000681. PubMed PMID: 30024425.

  10. Vyberg M, Diernæs C, Røge R, Nielsen S; ISIMM-NordiQC Immunoassay Performance
    Assessment Series, No. 2. NordiQC Assessments of Low Molecular Weight Keratin
    8/18 Immunoassays. Appl Immunohistochem Mol Morphol. 2017 Nov/Dec;25(10):673-678.
    doi: 10.1097/PAI.0000000000000603. PubMed PMID: 29116958.

  11. Røge R, Nielsen S, Bzorek M, Vyberg M; ISIMM-NordiQC Immunoassay Performance  Assessment Series, No. 1. NordiQC Assessments of SOX10 Immunoassays. Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):377-380. doi: 10.1097/PAI.0000000000000536. PubMed PMID: 28549040.

  12. Røge R, Vyberg M, Nielsen S. Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3. Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):381-385. doi: 10.1097/PAI.0000000000000534. PubMed PMID: 28697065.

  13. Vyberg M, Nielsen S. Proficiency testing in immunohistochemistry-experiences from Nordic Immunohistochemical Quality Control (NordiQC). Virchows Arch. 2016 Jan;468(1):19-29. doi: 10.1007/s00428-015-1829-1. Epub 2015 Aug 26. PubMed PMID: 26306713; PubMed Central PMCID: PMC4751198

  14. Torlakovic EE, Nielsen S, Vyberg M, Taylor CR. Getting controls under control: the time is now for immunohistochemistry. J Clin Pathol. 2015 Nov;68(11):879-82. doi: 10.1136/jclinpath-2014-202705. Epub 2015 Aug 18. Review. PubMed PMID: 26286753; PubMed Central PMCID: PMC4680144.

  15. Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat 2015 Jun;41(6):486-95. doi: 10.1016/j.ctrv.2015.05.001. Epub 2015 May 8. Review. PubMed PMID: 25979846.

  16. Vyberg M, Nielsen S, Røge R, Sheppard B, Ranger-Moore J, Walk E, Gartemann J, Rohr UP, Teichgräber V. Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests. BMC Health Serv Res. 2015 Aug 29;15:352. doi: 10.1186/s12913-015-1018-6. PubMed PMID: 26318869; PubMed Central  PMCID: PMC4553016.

  17. Torlakovic EE, Nielsen S, Francis G, Garratt J, Gilks B, Goldsmith JD, Hornick JL, Hyjek E, Ibrahim M, Miller K, Petcu E, Swanson PE, Zhou X, Taylor CR, Vyberg M. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):1-18. doi: 10.1097/PAI.0000000000000163. Review. PubMed PMID: 25474126.